November 4, 2020 8:10am

Pre-open indications: 1 BUY and 5 SELLs

News: Bellicum Pharmaceuticals (BLCM) closed its offering of 1,04 M shares, pre-funded warrants to purchase 3,109,378 shares of common stock and accompanying warrants to purchase up to 4,149,378 shares of common stock; priced at $6.025

What I provide is an “intelligence daily” to ensure that shareholders are kept apprised based on a 24-hour surveillance of “our” universe, the RegMed/cell and gene therapy sector and its surrounding markets

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  My gift to you, I've kept RMi subscription FREE during these COVID-19 and volatile times

 

Dow futures are UP +0.33% (+91 points), S&P futures are UP +1.29% (+44 points) and NASDAQ futures are UP +3.08% (+347 points)

 

U.S. stock futures flied on Wednesday as gains were kept in check as the results of the presidential election failing to identify a winner;

European markets rose amid choppy trade as investors watch U.S. election results and the pan-European Stoxx 600 was up + 0.6% by late morning;

Asia-Pacific markets were higher, other than Hong Kong with the MSCI’s broadest index of Asia-Pacific shares outside Japan was little changed.

 

Data Docket: FHA mortgage rates set record lows, juicing refinance demand. Final euro zone purchasing manager’s index (PMI) readings for October came in at 50.0, down from 50.4 in September, indicating that the bloc’s economy stalled as coronavirus cases resurged across the continent. Australia’s retail turnover fell 1.1% in September 2020 on a seasonally-adjusted basis, according to the country’s Bureau of Statistics.

 

Henry’omics:

Markets are coming off a strong session …

“Traders also grappled with the possibility of a contested election result, which Wall Street strategists say could have major consequences for the stock market.” <CNBC>

Monday night’s post: RegMed Investors’ (RMi) closing bell: “markets need election clarity, whether we individually like it or not … https://www.regmedinvestors.com/articles/11618   

  • The Nasdaq closed UP +292.96 points (+1.85%);
  • The IBB closed up +1.77% and XBI closed UP +2.71%;
  • Sector volume was the usual LOW with 4 of the 30-upside having higher than the 3-month average volume with the increased volume of 2 of 4-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was down -1.58 points or -4.26% at 35.55;
  • Tuesday’s percentage (%) of the 30-upside were +0.13% (CLLS) to +12.23% (PGEN) while the 4-downside of -1.10% (RENE.L) to -9.55% (EDIT);

Q4’s: November, so far: 2 positive closes

Q4’s October: 1 neutral, 11 positive and 10 negative closes

Q3: July through September: 1 neutral, 28 positive and 34 negative closes with 2 holidays

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Maintaining Sell:

Biostage (BSTG) closed up +$0.09 to $1.47 with 450 shares traded after Monday’s flat at $1.38 with 102 shares traded, Friday’s +$0.02 to $1.38 with 523 shares traded, Thursday’s flat at $1.35 (after being up +$0.14 with pricing erosion with 16,972 shares traded – 3-month average = 5058 shares) and last Wednesday’s -$0.04 to $1.36 with 261 shares traded.

  • Question#1: WHAT has happened to the Mayo Clinic relationship and collaboration?

 

SELL into Strength:

BioLife Solutions (BLFS) closed up +$1.35 to $30.91 after Monday’s $29.56, Friday’s $28.71, Thursday’s $30.72 after last Wednesday’s $30.27 with NO aftermarket indication but, a “peaky” chart;

Solid Biosciences (SLDB) closed up +$0.12 to $3.31, after Monday’s $3.19 with a NEGATIVE -$0.20 or -6.04% aftermarket indication

CRISPR Therapeutics (CRSP) closed up +$0.66 to $86.82 after Monday’s $86.16 and Friday’s $91.82 with a POSITIVE +$0.33 or +0.38% aftermarket indication;

 

BUY from SELL:

Editas Medicine (EDIT) closed down -$2.99 to $28.31 after Monday’s +$0.36 to $31.30, Friday’s $30.94, Thursday’s $32.79 and last Wednesday’s $31.60 with a POSITIVE +$0.24 or +0.85% aftermarket indication

 

SELL into Strength from BUY:

Vericel (VCEL) closed up +$1.04 to $20.92 after Monday’s +$0.55 to $19.88, Friday’s $, Thursday’s $18.53 and last Wednesday’s $18.83 with a NEGATIVE -$1.02 or -4.88% aftermarket indication;

 

The BOTTOM LINE: Today is a wait and see opportunity however, the Nasdaq is booming. A quote from another, ““The race is closer than the market thought,” said Patrick Bennett, a strategist at Canadian Imperial Bank of Commerce. “Reflation is one thing, but a close result - and we are far from the end - is a market negative,” he said.”

Now we enter the big upswing in sector earnings’ LPS (loss-per-share) releases with the next month likely to remain volatile and uncertain.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.